{
    "Clinical Trial ID": "NCT00810797",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Exemestane)",
        "  Patients receive 25mg oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.",
        "  exemestane: Given orally",
        "  laboratory biomarker analysis: One year after completion of study treatment",
        "  quality-of-life assessment: One year after completion of study treatment",
        "  immunohistochemistry staining method: Correlative studies"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed metastatic carcinoma of the breast",
        "  Hormone receptor (estrogen receptor [ER] and/or progesterone receptor [PR]) positive disease (defined as: ER and/or PR positivity as >= 5% staining), as confirmed by immunohistochemistry (IHC) based on primary breast tissue or metastatic tissue",
        "  Postmenopausal, as defined by any of the following:",
        "  Natural menopause, with at least 1 year since last menses",
        "  Chemotherapy-induced menopause with at least 1 year from last menses and serum luteinizing hormone (LH)/follicle-stimulating hormone (FSH) and estradiol levels within the postmenopausal range",
        "  History of surgical or radiation-induced ovarian ablation",
        "  For women =< 56 years old and with a history of hysterectomy but at least one ovary intact, serum LH/FSH and estradiol levels must be within the postmenopausal range",
        "  Postmenopausal women with disease recurrence while receiving either tamoxifen or a non-steroidal aromatase inhibitor (AI) as adjuvant therapy (as long as adjuvant hormonal therapy was taken for 6 months before disease progression) or with disease recurrence following the discontinuation/completion of adjuvant hormonal therapy",
        "  Postmenopausal women with disease progression following either 0, 1 or 2 prior hormonal therapies for metastatic breast cancer, as long as the subject has had no prior exposure to exemestane (EXE)",
        "  Measurable or non-measurable (but evaluable) disease, as defined by RECIST criteria",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
        "  Neutrophil count >= 1.5 X 10^9 cells/L",
        "  Platelet count >= 100 X 10^9 cells/L",
        "  Serum creatinine =< 1.5 times upper limit of normal (ULN)",
        "  Total serum bilirubin =< 1.5 times ULN",
        "  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels =< 2.5 x ULN in patients without liver metastases or =< 5 times ULN in patients with liver metastases",
        "  Alkaline phosphatase =< 2.5 times the ULN for patients without bone or liver metastases",
        "  Subjects must have an estimated life expectancy of greater than 6 months",
        "Exclusion Criteria:",
        "  Prior exposure to EXE, whether in the adjuvant or metastatic setting",
        "  Prior history of any other cancer with the exception of non-melanoma skin cancer and treated in situ carcinoma of the cervix",
        "  Active or symptomatic central nervous system (CNS) metastasis (stable or treated brain metastasis allowed but patients must be off decadron, if given for CNS disease)",
        "  Hormone-receptor negative or unknown breast cancer",
        "  More than two prior chemotherapy regimen for treatment of metastatic disease (any prior chemotherapy given in the adjuvant setting is permitted)",
        "  Administration of any other anti-cancer therapy within 2 weeks of initiating study treatment; use of bisphosphonates, however, are permitted for patients with known bone metastases",
        "  Treatment with any other concurrent investigational agent or anti-tumor drug (chemotherapy, antibody therapy or other biologic agents), will not be permitted",
        "  Subjects who have had no prior exposure to endocrine therapy",
        "  Any uncontrolled medical co-morbidity or psychiatric disorder which interferes with the ability to provide informed consent or comply with study procedures"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival",
        "  Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.",
        "  Time frame: Until disease progression of death from any cause, up to 3 years",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Exemestane)",
        "  Arm/Group Description: Patients receive 25mg oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.",
        "  exemestane: Given orally",
        "  laboratory biomarker analysis: One year after completion of study treatment",
        "  quality-of-life assessment: One year after completion of study treatment",
        "  immunohistochemistry staining method: Correlative studies",
        "  Overall Number of Participants Analyzed: 36",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  4.3        (2.0 to 6.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/36 (11.11%)",
        "  Rectal hemorrhage * 1/36 (2.78%)",
        "  Disease progression * 1/36 (2.78%)",
        "  Device related infection * 1/36 (2.78%)",
        "  Skin infection * 1/36 (2.78%)",
        "  Hypotension * 1/36 (2.78%)"
    ]
}